Patents-Review.com
🔗 Permalink
Assignee profile:

NOVARTIS AG

City:

Basel

Country:

Switzerland

Published Applications:

4,124

Last publication date:

2026-06-18

Patent Grants:

3,337

Last grant date:

2026-09-22

Novartis AG is a multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world, with over 120,000 employees and operations in over 140 countries. Novartis produces a wide range of products, including prescription drugs, over-the-counter medications, vaccines, and consumer health products. The company also has a strong presence in the biotechnology sector, with research and development activities focused on developing new treatments for diseases such as cancer and multiple sclerosis.

Quarterly NOVARTIS AG Patent Applications

Top Inventors for applications by NOVARTIS AG

These are the the leading inventors for applications assigned to NOVARTIS AG:

Recent patent applications by NOVARTIS AG

NOVARTIS AG based in Basel, CH has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-06-18
US20260167744A1
Chemistry; metallurgy

ANTI-IGE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES

 #2 | 2026-06-18
US20260167743A1
Chemistry; metallurgy

ANTI-IGE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES

 #3 | 2026-03-26 ✅ Patent 12,741,024 granted on 2026-09-22
US20260083842A1
Human necessities

PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES

 #4 | 2026-02-26 ✅ Patent 12,702,711 granted on 2026-08-11
US20260053919A1
Human necessities

PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES

 #5 | 2026-02-05
US20260035473A1
Chemistry; metallurgy

BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view

 #6 | 2025-11-20
US20250353820A1
Chemistry; metallurgy

ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS

 #7 | 2025-09-25 ✅ Patent 12,544,438 granted on 2026-02-10
US20250295769A1
Human necessities

PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES

 #8 | 2025-09-18 ✅ Patent 12,723,096 granted on 2026-09-01
US20250289902A1
Chemistry; metallurgy

REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB

 #9 | 2025-09-18 ✅ Patent 12,617,774 granted on 2026-05-05
US20250289804A1
Chemistry; metallurgy

SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF

 #10 | 2025-09-04 ✅ Patent 12,485,173 granted on 2025-12-02
US20250279860A1
Electricity

PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES

 #11 | 2025-09-04 ✅ Patent 12,485,172 granted on 2025-12-02
US20250276062A1
Human necessities

PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES

 #12 | 2025-08-28 ✅ Patent 12,751,949 granted on 2026-10-06
US20250268895A1
Human necessities

Crystalline Forms of a BTK Inhibitor

 #13 | 2025-07-10
US20250223359A1
Chemistry; metallurgy

CD19 BINDING MOLECULES AND USES THEREOF

 #14 | 2025-06-26 ✅ Patent 12,594,333 granted on 2026-04-07
US20250205332A1
Human necessities

METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS

 #15 | 2025-06-05 ✅ Patent 12,492,265 granted on 2025-12-09
US20250179216A1
Chemistry; metallurgy

ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES

 #16 | 2025-06-05
US20250179063A2
Chemistry; metallurgy

SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE

 #17 | 2025-05-22 ✅ Patent 12,594,332 granted on 2026-04-07
US20250161445A1
Human necessities

METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS

 #18 | 2025-05-22 ✅ Patent 12,594,331 granted on 2026-04-07
US20250161444A1
Human necessities

METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS

 #19 | 2025-05-22 ✅ Patent 12,551,554 granted on 2026-02-17
US20250161443A1
Human necessities

METHODS OF ADMINISTERING SECUKINUMAB

 #20 | 2025-05-01
US20250136706A1
Chemistry; metallurgy

Methods For Prevention Of Graft Rejection In Xenotransplantation

 #21 | 2025-05-01 ✅ Patent 12,595,306 granted on 2026-04-07
US20250136685A1
Chemistry; metallurgy

TREM2 STABILIZING ANTIBODIES

 #22 | 2025-04-24 ✅ Patent 12,419,894 granted on 2025-09-23
US20250127785A1
Human necessities

Ribociclib Tablet

 #23 | 2025-02-27 ✅ Patent 12,600,769 granted on 2026-04-14
US20250066462A1
Chemistry; metallurgy

STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF

 #24 | 2025-02-20
US20250059181A1
Chemistry; metallurgy

Tetrahydro-Pyrido-Pyrimidine Derivatives

 #25 | 2025-02-13 ✅ Patent 12,760,031 granted on 2026-10-13
US20250051345A1
Chemistry; metallurgy

PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS

 #26 | 2025-01-30 ✅ Patent 12,378,222 granted on 2025-08-05
US20250034114A1
Chemistry; metallurgy

NLRP3 INFLAMMASOME INHIBITORS

 #27 | 2025-01-23 ✅ Patent 12,453,726 granted on 2025-10-28
US20250025453A1
Human necessities

METHODS OF USING FACTOR B INHIBITORS

 #28 | 2025-01-09
US20250011474A1
Chemistry; metallurgy

ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES

 #29 | 2025-01-02 ✅ Patent 12,365,690 granted on 2025-07-22
US20250002499A1
Chemistry; metallurgy

Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators

 #30 | 2025-01-02 ✅ Patent 12,252,482 granted on 2025-03-18
US20250002479A1
Chemistry; metallurgy

Pyrazolopyridine derivatives and uses thereof

 #31 | 2024-12-19 ✅ Patent 12,296,008 granted on 2025-05-13
US20240415961A1
Human necessities

Pharmaceutical products and stable liquid compositions of IL-17 antibodies

 #32 | 2024-11-28 ✅ Patent 12,344,651 granted on 2025-07-01
US20240390492A1
Human necessities

CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

 #33 | 2024-11-14
US20240376094A2
Chemistry; metallurgy

SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE

 #34 | 2024-10-31 ✅ Patent 12,497,616 granted on 2025-12-16
US20240360447A1
Chemistry; metallurgy

COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE

 #35 | 2024-10-31 ✅ Patent 12,679,834 granted on 2026-07-14
US20240360118A1
Chemistry; metallurgy

Bicyclic Compounds and their Uses

 #36 | 2024-10-31
US20240360082A1
Chemistry; metallurgy

SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS

 #37 | 2024-10-24 ✅ Patent 12,331,060 granted on 2025-06-17
US20240352030A1
Chemistry; metallurgy

N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF

 #38 | 2024-10-10 ✅ Patent 12,129,246 granted on 2024-10-29
US20240336598A1
Chemistry; metallurgy

Hydroquinazoline derivatives for the treatment of a disease or disorder

 #39 | 2024-09-26 ✅ Patent 12,338,290 granted on 2025-06-24
US20240317878A1
Chemistry; metallurgy

REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB

 #40 | 2024-09-26 ✅ Patent 12,331,104 granted on 2025-06-17
US20240317840A1
Chemistry; metallurgy

HEPATITIS B ANTIBODIES

 #41 | 2024-09-05 ✅ Patent 12,358,929 granted on 2025-07-15
US20240294546A1
Chemistry; metallurgy

NMDA RECEPTOR MODULATORS AND USES THEREOF

 #42 | 2024-09-05 ✅ Patent 12,714,739 granted on 2026-08-25
US20240293508A1
Human necessities

METHODS OF TREATING METABOLIC DISORDERS ASSOCIATED WITH LIPODYSTROPHIES AND DEFECTS IN INSULIN PRODUCTION OR SIGNALING

 #43 | 2024-08-22 ✅ Patent 12,758,539 granted on 2026-10-13
US20240277689A1
Human necessities

METHOD OF TREATING AN AUTOIMMUNE HEMATOLOGICAL DISORDER

 #44 | 2024-08-15 ✅ Patent 12,358,906 granted on 2025-07-15
US20240270738A1
Chemistry; metallurgy

UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS

 #45 | 2024-08-08 ✅ Patent 12,527,841 granted on 2026-01-20
US20240261372A1
Human necessities

FIBROBLAST GROWTH FACTOR-21-FC FUSION PROTEINS

 #46 | 2024-08-01 ✅ Patent 12,594,321 granted on 2026-04-07
US20240252538A1
Human necessities

TREATMENT OF CANCER USING CHIMERIC ANTIGEN RECEPTORS

 #47 | 2024-07-18 ✅ Patent 12,559,562 granted on 2026-02-24
US20240238396A1
Human necessities

TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR

 #48 | 2024-06-06 ✅ Patent 12,616,700 granted on 2026-05-05
US20240180913A1
Human necessities

THE THERAPEUTIC REGIMEN

 #49 | 2024-05-30 ✅ Patent 12,599,664 granted on 2026-04-14
US20240173404A1
Human necessities

PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES

 #50 | 2024-05-16 ✅ Patent 12,441,733 granted on 2025-10-14
US20240158399A1
Chemistry; metallurgy

N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives

 #51 | 2024-05-16 ✅ Patent 12,172,984 granted on 2024-12-24
US20240158374A1
Chemistry; metallurgy

Pyrazolopyridine derivatives and uses thereof

 #52 | 2024-05-09 ✅ Patent 12,570,754 granted on 2026-03-10
US20240150485A1
Chemistry; metallurgy

REGIMENS AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB

 #53 | 2024-04-11 ✅ Patent 12,491,231 granted on 2025-12-09
US20240115661A1
Human necessities

METHODS OF TREATING METABOLIC DISORDERS WITH FGF21 VARIANTS

 #54 | 2024-03-21 ✅ Patent 12,180,291 granted on 2024-12-31
US20240092918A1
Chemistry; metallurgy

Anti-CCR7 antibody drug conjugates

 #55 | 2024-03-14
US20240082215A1
Human necessities

USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER

 #56 | 2024-02-29 ✅ Patent 12,544,380 granted on 2026-02-10
US20240066034A1
Human necessities

COMBINATION THERAPY FOR THE TREATMENT OF CANCER

 #57 | 2024-02-15 ✅ Patent 12,649,781 granted on 2026-06-09
US20240052024A1
Chemistry; metallurgy

METHODS FOR TREATING OCULAR DISEASES

 #58 | 2024-02-15
US20240050597A1
Human necessities

RADIOLABELLED ALPHA-V BETA-3 AND/OR ALPHA-V BETA-5 INTEGRINS ANTAGONIST FOR USE AS THERAGNOSTIC AGENT

 #59 | 2024-02-15
US20240050408A1
Human necessities

USE OF MGLUR5 ANTAGONISTS FOR TREATING AMPHETAMINE ADDICTION

 #60 | 2024-02-08 ✅ Patent 12,157,737 granted on 2024-12-03
US20240043425A1
Chemistry; metallurgy

Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof

 #61 | 2024-02-01
US20240033358A1
Human necessities

COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLS

 #62 | 2024-01-25 ✅ Patent 12,655,115 granted on 2026-06-16
US20240025866A1
Chemistry; metallurgy

SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS

 #63 | 2024-01-18 ✅ Patent 12,668,569 granted on 2026-06-30
US20240018099A1
Chemistry; metallurgy

SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS

 #64 | 2024-01-18 ✅ Patent 12,544,379 granted on 2026-02-10
US20240016808A1
Human necessities

COMBINATION THERAPY FOR THE TREATMENT OF CANCER

 #65 | 2024-01-11 ✅ Patent 12,679,814 granted on 2026-07-14
US20240010623A1
Chemistry; metallurgy

SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS

 #66 | 2024-01-11
US20240009215A1
Human necessities

COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION

 #67 | 2024-01-04
US20240002843A1
Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES

 #68 | 2023-12-28 ✅ Patent 12,084,424 granted on 2024-09-10
US20230416211A1
Chemistry; metallurgy

Compounds and compositions for treating conditions associated with NLRP activity

 #69 | 2023-12-14 ✅ Patent 12,077,571 granted on 2024-09-03
US20230399382A1
Chemistry; metallurgy

Polyomavirus neutralizing antibodies

 #70 | 2023-12-14 ✅ Patent 12,605,451 granted on 2026-04-21
US20230398224A1
Human necessities

TARGETED PLASMA PROTEIN DEGRADATION

 #71 | 2023-12-07 ✅ Patent 12,600,728 granted on 2026-04-14
US20230391782A1
Chemistry; metallurgy

INTERLEUKIN-17 INHIBITORS

 #72 | 2023-11-23 ✅ Patent 12,441,737 granted on 2025-10-14
US20230374029A1
Chemistry; metallurgy

MANUFACTURE OF COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2

 #73 | 2023-11-16 ✅ Patent 12,410,255 granted on 2025-09-09
US20230365674A1
Chemistry; metallurgy

NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE

 #74 | 2023-11-16 ✅ Patent 12,209,096 granted on 2025-01-28
US20230365580A1
Chemistry; metallurgy

Compounds and compositions for inducing chondrogenesis

 #75 | 2023-11-16 ✅ Patent 12,729,202 granted on 2026-09-08
US20230365571A1
Chemistry; metallurgy

COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS

 #76 | 2023-11-16 ✅ Patent 12,338,220 granted on 2025-06-24
US20230365511A1
Chemistry; metallurgy

Antiviral Pyrazolopiridinone Compounds

 #77 | 2023-11-09 ✅ Patent 12,655,226 granted on 2026-06-16
US20230357717A1
Chemistry; metallurgy

CELL SECRETED MINIBODIES AND USES THEREOF

 #78 | 2023-11-09
US20230355582A1
Human necessities

MODIFIED RELEASE FORMULATION

 #79 | 2023-11-09 ✅ Patent 12,533,340 granted on 2026-01-27
US20230355577A1
Human necessities

TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER

 #80 | 2023-10-12 ✅ Patent 12,071,441 granted on 2024-08-27
US20230322793A1
Chemistry; metallurgy

10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza

 #81 | 2023-09-28 ✅ Patent 12,642,789 granted on 2026-06-02
US20230301970A1
Human necessities

CARBOXAMIDE DERIVATIVES

 #82 | 2023-09-28 ✅ Patent 12,458,532 granted on 2025-11-04
US20230301831A1
Human necessities

MULTI-DOSE OCULAR FLUID DELIVERY SYSTEM

 #83 | 2023-09-21 ✅ Patent 12,275,795 granted on 2025-04-15
US20230295322A1
Chemistry; metallurgy

Binding molecules against BCMA and uses thereof

 #84 | 2023-09-21 ✅ Patent 12,522,654 granted on 2026-01-13
US20230295291A1
Chemistry; metallurgy

ENGINEERED HETERODIMERIC PROTEINS

 #85 | 2023-08-24 ✅ Patent 12,384,758 granted on 2025-08-12
US20230265067A1
Chemistry; metallurgy

CRYSTALLINE FORM OF LNP023

 #86 | 2023-08-10 ✅ Patent 11,952,428 granted on 2024-04-09
US20230250179A1
Chemistry; metallurgy

BCMA chimeric antigen receptors and uses thereof

 #87 | 2023-07-06 ✅ Patent 12,122,761 granted on 2024-10-22
US20230212139A1
Chemistry; metallurgy

2-azaspiro[3.4]octane derivatives as M4 agonists

 #88 | 2023-06-29 ✅ Patent 12,084,442 granted on 2024-09-10
US20230203032A1
Chemistry; metallurgy

Naphthyridinone derivatives for the treatment of a disease or disorder

 #89 | 2023-06-29 ✅ Patent 12,433,949 granted on 2025-10-07
US20230201353A1
Human necessities

SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS

 #90 | 2023-06-15 ✅ Patent 11,939,389 granted on 2024-03-26
US20230183368A1
Chemistry; metallurgy

BCMA chimeric antigen receptors and uses thereof

 #91 | 2023-06-01 ✅ Patent 12,735,502 granted on 2026-09-15
US20230167193A1
Chemistry; metallurgy

IMMUNOGLOBULIN VARIANTS

 #92 | 2023-06-01 ✅ Patent 12,595,305 granted on 2026-04-07
US20230167174A1
Chemistry; metallurgy

TREM2 STABILIZING ANTIBODIES

 #93 | 2023-06-01 ✅ Patent 12,473,273 granted on 2025-11-18
US20230167100A1
Chemistry; metallurgy

QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2

 #94 | 2023-05-18
US20230151106A1
Chemistry; metallurgy

OFATUMUMAB FOR TREATING MS WHILE MAINTAINING SERUM IgG

 #95 | 2023-05-18 ✅ Patent 12,194,278 granted on 2025-01-14
US20230149629A1
Human necessities

Injection device and injection solution transferring system

 #96 | 2023-04-27
US20230128499A1
Chemistry; metallurgy

BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES

 #97 | 2023-04-20 ✅ Patent 12,559,748 granted on 2026-02-24
US20230118337A1
Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES

 #98 | 2023-04-13 ✅ Patent 12,048,837 granted on 2024-07-30
US20230113993A1
Human necessities

Syringe

 #99 | 2023-04-13 ✅ Patent 12,280,041 granted on 2025-04-22
US20230112980A1
Human necessities

Compounds and compositions for inducing chondrogenesis

 #100 | 2023-04-06 ✅ Patent 11,787,785 granted on 2023-10-17
US20230108325A1
Chemistry; metallurgy

Pyrazolopyridine derivatives and uses thereof

Also check out NOVARTIS AG's (Basel, Switzerland) applicant profile with 1,850 patent applications submitted.

AssigneeID:

1602 ⎘